HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo.

AbstractBACKGROUND:
Irofulven (MGI 114), a novel antitumor agent synthesized from the natural product illudin S, has a unique mechanism of action involving macromolecule adduct formation, S-phase arrest and induction of apoptosis.
MATERIALS AND METHODS:
This study utilized MiaPaCa pancreatic xenografts to demonstrate irofulven antitumor activity using either a daily or intermittent dosing schedule. Additionally, irofulven and gemcitabine were tested in vitro and in vivo to assess the anticancer activity of the combination.
RESULTS:
Both dosing regimens of irofulven demonstrated curative activity against the MiaPaCa xenografts. Similar activity of irofulven on the intermittent schedule was observed at lower total doses compared to the daily dosing schedule. Furthermore, enhanced antitumor activity was observed when irofulven and gemcitabine were combined compared to single agent activity.
CONCLUSION:
These results support further clinical characterization of intermittent irofulven dosing schedules and suggest that irofulven combined with gemcitabine may have activity in patients with pancreatic tumors.
AuthorsEmily S Van Laar, Stephanie Roth, Steven Weitman, John R MacDonald, Stephen J Waters
JournalAnticancer research (Anticancer Res) 2004 Jan-Feb Vol. 24 Issue 1 Pg. 59-65 ISSN: 0250-7005 [Print] Greece
PMID15015576 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Sesquiterpenes
  • Deoxycytidine
  • irofulven
  • Gemcitabine
Topics
  • Animals
  • Antineoplastic Agents, Alkylating (pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Cell Line, Tumor
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Drug Administration Schedule
  • Drug Synergism
  • Female
  • Humans
  • Inhibitory Concentration 50
  • Mice
  • Mice, Nude
  • Pancreatic Neoplasms (drug therapy)
  • Sesquiterpenes (administration & dosage, pharmacology)
  • Xenograft Model Antitumor Assays
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: